Overview
Invasive fungal sinusitis (IFS) is a severe infection characterized by fungal invasion of the paranasal sinuses, often leading to significant morbidity and mortality. It can occur in immunocompromised individuals, particularly those with underlying conditions like diabetes and those treated with immunosuppressive therapies, including corticosteroids 1.Diagnosis
Clinical Presentation: Symptoms include facial pain, fever, headache, and nasal discharge, often progressing rapidly 1.
Imaging: CT or MRI showing characteristic sinus opacification, bony erosion, or soft tissue abnormalities 1.
Laboratory Tests: Nasal or sinus aspirates for fungal cultures and histopathology 1.
PCR Testing: Detection of fungal DNA in respiratory samples, though sensitivity varies 1.
Risk Factors: Presence of diabetes, steroid use, and recent COVID-19 infection identified as significant risk factors 1.
Grading: Classification systems like the Lund-Mackay staging can help assess disease severity 1.Management
First-Line Treatment: Amphotericin B or echinocandins (e.g., caspofungin) for severe cases 1.
Adjunctive Therapy: Surgical debridement for extensive necrosis or complications 1.
Supportive Care: Management of underlying conditions (e.g., glycemic control in diabetes) 1.
Duration: Treatment duration often guided by clinical response and fungal clearance 1.
Monitoring: Regular follow-up imaging and laboratory tests to assess response to therapy 1.
COVID-19 Considerations: Continued monitoring for IFS in patients with recent COVID-19 and steroid exposure 1.Special Populations
Diabetes: Increased risk with odds ratio of 6.09; close monitoring and glycemic control essential 1.
Steroid Use: Significant risk factor with odds ratio of 2.21; minimize unnecessary steroid exposure 1.
COVID-19: Recent infection increases risk with odds ratio of 1.82; heightened vigilance recommended 1.Key Recommendations
Screen and Monitor High-Risk Patients: Regularly screen patients with diabetes, recent steroid use, and those recovering from COVID-19 for signs of IFS (Evidence: Moderate) 1.
Initiate Early Antifungal Therapy: Start with potent antifungal agents like echinocandins or amphotericin B in suspected cases (Evidence: Moderate) 1.
Consider Surgical Intervention: For patients with extensive disease or complications, surgical debridement is crucial (Evidence: Moderate) 1.References
1 Chen H, Yu L, Wang L, Zhang J, Yan X, Jiang Y. Demographic characteristics and risk factors for invasive fungal sinusitis in the context of COVID-19: A systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2024. link